{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:40:24Z","timestamp":1791333624212,"version":"4.3.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.bcp.2014.01.013","type":"journal-article","created":{"date-parts":[[2014,1,22]],"date-time":"2014-01-22T16:31:09Z","timestamp":1390408269000},"page":"540-547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["New perspectives on the role of tau in Alzheimer's disease. Implications for therapy"],"prefix":"10.1016","volume":"88","author":[{"given":"Miguel","family":"Medina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bcp.2014.01.013_bib0005","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1091\/mbc.3.10.1141","article-title":"Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau","volume":"3","author":"Drechsel","year":"1992","journal-title":"Mol Biol Cell"},{"issue":"22","key":"10.1016\/j.bcp.2014.01.013_bib0010","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1073\/pnas.92.22.10369","article-title":"Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes","volume":"92","author":"LoPresti","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1083\/jcb.143.3.777","article-title":"Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease","volume":"143","author":"Ebneth","year":"1998","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0169-328X(86)90033-1","article-title":"Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2","volume":"387","author":"Neve","year":"1986","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/j.1460-2075.1989.tb03390.x","article-title":"Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain","volume":"8","author":"Goedert","year":"1989","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.bcp.2014.01.013_bib0030","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0896-6273(89)90050-0","article-title":"The microtubule binding domain of tau protein","volume":"2","author":"Lee","year":"1989","journal-title":"Neuron"},{"issue":"13","key":"10.1016\/j.bcp.2014.01.013_bib0035","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","article-title":"Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization","volume":"9","author":"Goedert","year":"1990","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0040","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1083\/jcb.101.4.1371","article-title":"The distribution of tau in the mammalian central nervous system","volume":"101","author":"Binder","year":"1985","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0955-0674(05)80038-9","article-title":"Tau protein and Alzheimer's disease","volume":"2","author":"Kosik","year":"1990","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"10.1016\/j.bcp.2014.01.013_bib0050","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0055","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.bcp.2014.01.013_bib0060","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative disorders","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"issue":"17","key":"10.1016\/j.bcp.2014.01.013_bib0065","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1007\/s00018-007-7220-x","article-title":"Tauopathies","volume":"64","author":"Hernandez","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0070","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1468-1331.2008.02513.x","article-title":"Tauopaties with parkinsonism clinical spectrum: neuropathological basis, biological markers, and treatment options","volume":"16","author":"Ludolph","year":"2009","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.1016\/j.bcp.2014.01.013_bib0075","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","article-title":"Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease","volume":"91","author":"Alonso","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.bcp.2014.01.013_bib0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nm0796-783","article-title":"Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules","volume":"2","author":"Alonso","year":"1996","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0014-5793(92)80767-B","article-title":"The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs","volume":"307","author":"Gustke","year":"1992","journal-title":"FEBS Lett"},{"issue":"13","key":"10.1016\/j.bcp.2014.01.013_bib0090","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1016\/S0021-9258(17)38495-8","article-title":"Microtubule-associated protein tau. A component of Alzheimer paired helical filaments","volume":"261","author":"Grundke-Iqbal","year":"1986","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0006-8993(89)91117-7","article-title":"Anomalous accumulation of tau and ubiquitin immunoreactivities in rat brain caused by protease inhibition and by normal aging: a clue to PHF pathogenesis","volume":"498","author":"Ivy","year":"1989","journal-title":"Brain Res"},{"issue":"14","key":"10.1016\/j.bcp.2014.01.013_bib0100","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1523\/JNEUROSCI.0587-07.2007","article-title":"Accumulation of pathological tau species and memory loss in a conditional model of tauopathy","volume":"27","author":"Berger","year":"2007","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00401-009-0486-3","article-title":"Mechanisms of tau-induced neurodegeneration","volume":"118","author":"Iqbal","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"3 Pt 1","key":"10.1016\/j.bcp.2014.01.013_bib0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/WNL.42.3.631","article-title":"Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease","volume":"42","author":"Arriagada","year":"1992","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2014.01.013_bib0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbadis.2004.08.007","article-title":"Mutations causing neurodegenerative tauopathies","volume":"1739","author":"Goedert","year":"2005","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.bcp.2014.01.013_bib0120","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"Tau is essential to \u03b2-amyloid-induced neurotoxicity","volume":"99","author":"Rapoport","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5825","key":"10.1016\/j.bcp.2014.01.013_bib0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid \u03b2-induced deficits in an Alzheimer's disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"issue":"5830","key":"10.1016\/j.bcp.2014.01.013_bib0130","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.316.5830.1416","article-title":"A new take on tau","volume":"316","author":"Marx","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/157488911794079091","article-title":"Recent developments in tau-based therapeutics for neurodegenerative diseases","volume":"6","author":"Medina","year":"2011","journal-title":"Recent Pat CNS Drug Discov"},{"key":"10.1016\/j.bcp.2014.01.013_bib0140","first-page":"2010","article-title":"Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease","author":"Jaworski","year":"2010","journal-title":"Int J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.bcp.2014.01.013_bib0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"17","key":"10.1016\/j.bcp.2014.01.013_bib0155","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s00018-007-7221-9","article-title":"Developing pharmacological therapies for Alzheimer disease","volume":"64","author":"Iqbal","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10.1016\/j.bcp.2014.01.013_bib0160","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nrd2959","article-title":"Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies","volume":"8","author":"Brunden","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0165","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005072-199902000-00008","article-title":"Neurons may live for decades with neurofibrillary tangles","volume":"58","author":"Morsch","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"issue":"22","key":"10.1016\/j.bcp.2014.01.013_bib0170","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1523\/JNEUROSCI.4637-04.2005","article-title":"Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms","volume":"25","author":"Andorfer","year":"2005","journal-title":"J Neurosci"},{"issue":"7","key":"10.1016\/j.bcp.2014.01.013_bib0175","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/NEN.0b013e3181a9fc66","article-title":"Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy","volume":"68","author":"de Calignon","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"issue":"30","key":"10.1016\/j.bcp.2014.01.013_bib0180","doi-asserted-by":"crossref","first-page":"22042","DOI":"10.1074\/jbc.M112.436402","article-title":"Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models","volume":"288","author":"Zhang","year":"2013","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nurt.2008.05.006","article-title":"Tau-based treatment strategies in neurodegenerative diseases","volume":"5","author":"Schneider","year":"2008","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0190","first-page":"533","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic","volume":"11","author":"Medina","year":"2008","journal-title":"Curr Opin Drug Discov Dev"},{"issue":"25","key":"10.1016\/j.bcp.2014.01.013_bib0195","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.2174\/138161210793176581","article-title":"Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease","volume":"16","author":"Medina","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bcp.2014.01.013_bib0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fnmol.2011.00024","article-title":"Modulation of GSK-3 as a therapeutic strategy on tau pathologies","volume":"4","author":"Medina","year":"2011","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"10.1016\/j.bcp.2014.01.013_bib0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.bp.110.080044","article-title":"Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial","volume":"198","author":"Forlenza","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0210","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib","volume":"287","author":"Dom\u00ednguez","year":"2012","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0215","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2014.01.013_bib0220","unstructured":"Press release: http:\/\/www.noscira.com\/media\/docs\/Nota_Prensa20072012_en.pdf."},{"issue":"23","key":"10.1016\/j.bcp.2014.01.013_bib0225","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr Med Chem"},{"issue":"31","key":"10.1016\/j.bcp.2014.01.013_bib0230","doi-asserted-by":"crossref","first-page":"13888","DOI":"10.1073\/pnas.1009038107","article-title":"Sodium selenate mitigates tau pathology: neurodegeneration, and functional deficits in Alzheimer's disease models","volume":"107","author":"van Eersel","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0235","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1479-8301.2009.00289.x","article-title":"Novel therapeutic strategies for neurodegenerative disease","volume":"9","author":"Tanimukai","year":"2009","journal-title":"Psychogeriatrics"},{"issue":"11","key":"10.1016\/j.bcp.2014.01.013_bib0240","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1096\/fj.10-158477","article-title":"The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment","volume":"24","author":"Wang","year":"2010","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0245","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.expneurol.2009.07.035","article-title":"Abeta and tau in Alzheimer's disease: an early interim report","volume":"223","author":"Golde","year":"2010","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0250","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1471-4159.1999.0721283.x","article-title":"Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide","volume":"72","author":"Bassan","year":"1999","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent: NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory: increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.1016\/j.bcp.2014.01.013_bib0265","doi-asserted-by":"crossref","first-page":"e51458","DOI":"10.1371\/journal.pone.0051458","article-title":"The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities","volume":"7","author":"Oz","year":"2012","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bcp.2014.01.013_bib0270","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2174\/156720510793611628","article-title":"Tau pathology and future therapeutics","volume":"7","author":"Gozes","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"5\u20136","key":"10.1016\/j.bcp.2014.01.013_bib0275","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348347","article-title":"AL-108-211 Study. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment","volume":"35","author":"Morimoto","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"10.1016\/j.bcp.2014.01.013_bib0280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2174\/156720510793611600","article-title":"Tau aggregation is a therapeutic target for Alzheimer's disease","volume":"7","author":"Takashima","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"10","key":"10.1016\/j.bcp.2014.01.013_bib0285","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/anie.200802621","article-title":"Development of tau aggregation inhibitors for Alzheimer's disease","volume":"48","author":"Bulic","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"10.1016\/j.bcp.2014.01.013_bib0290","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/jm3017317","article-title":"Progress and developments in tau aggregation inhibitors for Alzheimer disease","volume":"56","author":"Bulic","year":"2013","journal-title":"J Med Chem"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2014.01.013_bib0295","doi-asserted-by":"crossref","first-page":"T167","DOI":"10.1016\/j.jalz.2008.05.438","article-title":"Tau aggregation inhibitor (TAI) therapy with Rember\u2122 arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks","volume":"4","author":"Wischik","year":"2008","journal-title":"Alz Dement"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0300","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.00773-07","article-title":"Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum","volume":"52","author":"Buchholz","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0305","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12603-009-0046-5","article-title":"Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy","volume":"13","author":"Wischik","year":"2009","journal-title":"J Nutr Health Aging"},{"issue":"August (2)","key":"10.1016\/j.bcp.2014.01.013_bib0310","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1471-4159.1992.tb09432.x","article-title":"Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein","volume":"59","author":"Khatoon","year":"1992","journal-title":"J Neurochem"},{"issue":"6480","key":"10.1016\/j.bcp.2014.01.013_bib0315","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/369488a0","article-title":"Altered microtubule organization in small-calibre axons of mice lacking tau protein","volume":"369","author":"Harada","year":"1994","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2014.01.013_bib0320","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1083\/jcb.150.5.989","article-title":"Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes","volume":"150","author":"Takei","year":"2000","journal-title":"J Cell Biol"},{"issue":"6","key":"10.1016\/j.bcp.2014.01.013_bib0325","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1242\/jcs.114.6.1179","article-title":"Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice","volume":"114","author":"Dawson","year":"2001","journal-title":"J Cell Sci"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/82868","article-title":"Neurotrophins are required for nerve growth during development","volume":"4","author":"Tucker","year":"2001","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0335","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-\u03b2 toxicity in Alzheimer's disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2014.01.013_bib0340","first-page":"873270","article-title":"Lessons from tau-deficient mice","volume":"2012","author":"Ke","year":"2012","journal-title":"Int J Alzheimers Dis"},{"issue":"6257","key":"10.1016\/j.bcp.2014.01.013_bib0345","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/343461a0","article-title":"Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons","volume":"343","author":"Caceres","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0350","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.neuroscience.2010.04.037","article-title":"Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease","volume":"169","author":"Dawson","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2014.01.013_bib0355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fneur.2013.00072","article-title":"What renders TAU toxic","volume":"4","author":"G\u00f6tz","year":"2013","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.bcp.2014.01.013_bib0360","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00401-012-0987-3","article-title":"Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau","volume":"123","author":"Van der Jeugd","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"18","key":"10.1016\/j.bcp.2014.01.013_bib0365","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1111\/febs.12250","article-title":"Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology","volume":"280","author":"Hochgr\u00e4fe","year":"2013","journal-title":"FEBS J"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0370","first-page":"497","article-title":"Increased tau messenger RNA in Alzheimer's disease hippocampus","volume":"137","author":"Barton","year":"1990","journal-title":"Am J Pathol"},{"issue":"13","key":"10.1016\/j.bcp.2014.01.013_bib0375","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1523\/JNEUROSCI.19-13-05245.1999","article-title":"Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus","volume":"19","author":"Tatebayashi","year":"1999","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0380","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3233\/JAD-130824","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression","volume":"37","author":"Qian","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.bcp.2014.01.013_bib0385","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jnc.12437","article-title":"Alternative polyadenylation and miR-34 family members regulate tau expression","volume":"127","author":"Dickson","year":"2013","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0390","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.nbd.2006.10.018","article-title":"The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts","volume":"25","author":"Myers","year":"2007","journal-title":"Neurobiol Dis"},{"issue":"18","key":"10.1016\/j.bcp.2014.01.013_bib0395","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1093\/hmg\/dds238","article-title":"MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies","volume":"21","author":"Trabzuni","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.bcp.2014.01.013_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2013.01.017","article-title":"Variation in tau isoform expression in different brain regions and disease states","volume":"34","author":"Majounie","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"8","key":"10.1016\/j.bcp.2014.01.013_bib0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006361","article-title":"The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease","volume":"2","author":"Ihara","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bcp.2014.01.013_bib0410","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2013.03.001","article-title":"Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system","volume":"105","author":"Lee","year":"2013","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0415","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1042\/BST20120071","article-title":"Degradation of tau protein by autophagy and proteasomal pathways","volume":"40","author":"Wang","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bcp.2014.01.013_bib0420","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0306-4522(87)90063-7","article-title":"Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease","volume":"23","author":"Saper","year":"1987","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2014.01.013_bib0425","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/nbdi.1997.0164","article-title":"Transneuronal degeneration in the spread of Alzheimer's disease pathology: immunohistochemical evidence for the transmission of tau hyperphosphorylation","volume":"4","author":"Su","year":"1997","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.bcp.2014.01.013_bib0430","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3233\/JAD-2010-1273","article-title":"Interneuronal transfer of human tau between Lamprey central neurons in situ","volume":"19","author":"Kim","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2014.01.013_bib0435","doi-asserted-by":"crossref","first-page":"42751","DOI":"10.1074\/jbc.M112.380642","article-title":"Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies","volume":"287","author":"Karch","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2014.01.013_bib0440","doi-asserted-by":"crossref","first-page":"124ra129","DOI":"10.1126\/scitranslmed.3003771","article-title":"A human stem cell model of early Alzheimer's disease pathology in Down syndrome","volume":"4","author":"Shi","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bcp.2014.01.013_bib0445","doi-asserted-by":"crossref","first-page":"e36873","DOI":"10.1371\/journal.pone.0036873","article-title":"Hyperphosphorylation and cleavage at D421 enhance tau secretion","volume":"7","author":"Plouffe","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2014.01.013_bib0450","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nbd.2012.05.021","article-title":"Constitutive secretion of tau protein by an unconventional mechanism","volume":"48","author":"Chai","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0455","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/embor.2013.15","article-title":"Physiological release of endogenous tau is stimulated by neuronal activity","volume":"14","author":"Pooler","year":"2013","journal-title":"EMBO Rep"},{"key":"10.1016\/j.bcp.2014.01.013_bib0460","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3171\/2008.9.JNS08584","article-title":"Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury","volume":"110","author":"Marklund","year":"2009","journal-title":"J Neurosurg"},{"key":"10.1016\/j.bcp.2014.01.013_bib0465","doi-asserted-by":"crossref","first-page":"13110","DOI":"10.1523\/JNEUROSCI.2569-11.2011","article-title":"In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice","volume":"31","author":"Yamada","year":"2011","journal-title":"J Neurosci"},{"key":"10.1016\/j.bcp.2014.01.013_bib0470","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/brain\/awr286","article-title":"Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury","volume":"135","author":"Magnoni","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2014.01.013_bib0475","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.mcn.2007.12.010","article-title":"Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells","volume":"37","author":"Gomez-Ramos","year":"2008","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.bcp.2014.01.013_bib0480","doi-asserted-by":"crossref","first-page":"32539","DOI":"10.1074\/jbc.M110.145003","article-title":"Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau","volume":"285","author":"Diaz-Hernandez","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.febslet.2011.11.022","article-title":"Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles","volume":"586","author":"Sim\u00f3n","year":"2012","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bcp.2014.01.013_bib0490","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fneur.2013.00074","article-title":"The involvement of cholinergic neurons in the spreading of tau pathology","volume":"4","author":"Sim\u00f3n","year":"2013","journal-title":"Front Neurol"},{"key":"10.1016\/j.bcp.2014.01.013_bib0495","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","article-title":"Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease","volume":"287","author":"Saman","year":"2012","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0500","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12031-011-9576-5","article-title":"Immunotherapy for tauopathies","volume":"45","author":"Gu","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"5","key":"10.1016\/j.bcp.2014.01.013_bib0505","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2174\/156720509789207930","article-title":"Tau-focused immunotherapy for Alzheimer's disease and related tauopathies","volume":"6","author":"Sigurdsson","year":"2009","journal-title":"Curr Alzheimer Res"},{"issue":"34","key":"10.1016\/j.bcp.2014.01.013_bib0510","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J Neurosci"},{"issue":"10","key":"10.1016\/j.bcp.2014.01.013_bib0515","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/archneur.63.10.1459","article-title":"Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein","volume":"63","author":"Rosenmann","year":"2006","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0520","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.expneurol.2010.05.010","article-title":"Efficacy safety of immunization with phosphorylated tau against neurofibrillary and tangles in mice","volume":"224","author":"Boimel","year":"2010","journal-title":"Exp Neurol"},{"issue":"49","key":"10.1016\/j.bcp.2014.01.013_bib0525","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","article-title":"Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model","volume":"30","author":"Boutajangout","year":"2010","journal-title":"J Neurosci"},{"issue":"12","key":"10.1016\/j.bcp.2014.01.013_bib0530","doi-asserted-by":"crossref","first-page":"e26860","DOI":"10.1371\/journal.pone.0026860","article-title":"Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice","volume":"6","author":"Bi","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0535","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/156720512800492503","article-title":"Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach","volume":"9","author":"Troquier","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"39","key":"10.1016\/j.bcp.2014.01.013_bib0540","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J Biol Chem."},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0545","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J Neurochem"},{"key":"10.1016\/j.bcp.2014.01.013_bib0550","doi-asserted-by":"crossref","unstructured":"d\u2019Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 2013;8(4):e62402.","DOI":"10.1371\/journal.pone.0062402"},{"key":"10.1016\/j.bcp.2014.01.013_bib0555","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JAD-2008-15203","article-title":"Chaperone-like antibodies targeting misfolded tau protein: New vistas in the immunotherapy of neurodegenerative foldopathies","volume":"15","author":"Zilka","year":"2008","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.bcp.2014.01.013_bib0560","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.bcp.2014.01.013_bib0565","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0570","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0575","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3233\/JAD-2008-14411","article-title":"Tay aggregates: toxic, inert, or protective species?","volume":"14","author":"Bretteville","year":"2008","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.bcp.2014.01.013_bib0580","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JAD-2008-14415","article-title":"Is tau aggregation toxic or protective?","volume":"14","author":"Congdon","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2014.01.013_bib0585","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/srep00700","article-title":"Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau","volume":"2","author":"Lasagna-Reeves","year":"2012","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.bcp.2014.01.013_bib0590","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"Abeta oligomers \u2013 a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.bcp.2014.01.013_bib0595","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.coi.2009.05.001","article-title":"Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders","volume":"21","author":"Kayed","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.bcp.2014.01.013_bib0600","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-2008-15202","article-title":"Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies","volume":"15","author":"Sigurdsson","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.bcp.2014.01.013_bib0605","first-page":"33081","volume":"288","author":"Gu","year":"2013","journal-title":"Two novel tau antibodies targeting the 396\/404 region are primarily taken up by neurons and reduce tau pathology. J Biol Chem."},{"issue":"49","key":"10.1016\/j.bcp.2014.01.013_bib0610","doi-asserted-by":"crossref","first-page":"35452","DOI":"10.1074\/jbc.M113.491001","article-title":"Antibody uptake into neurons occurs primarily via clathrin dependent Fc\u03b3 receptor endocytosis, and is a prerequisite for acute tau clearance","volume":"288","author":"Congdon","year":"2013","journal-title":"J Biol Chem"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295214000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T08:12:59Z","timestamp":1648109579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295214000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006295214000379"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.013","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New perspectives on the role of tau in Alzheimer's disease. Implications for therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2014.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}